Provided By GlobeNewswire
Last update: Apr 16, 2025
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs
EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa.
Read more at globenewswire.com